Welcome to LookChem.com Sign In|Join Free

CAS

  • or

62995-79-3

Post Buying Request

62995-79-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

62995-79-3 Usage

Description

CHEMBRDG-BB 4012656, a chemical compound with the molecular formula C12H15NO3, belongs to the benzo[c]phenanthridine alkaloids class. It has been studied for its potential pharmacological properties, such as antiviral, anti-inflammatory, and anticancer activities, as well as its antioxidant properties. CHEMBRDG-BB 4012656 is considered a promising natural source for drug development, although further research is needed to fully understand its mechanisms of action and potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
CHEMBRDG-BB 4012656 is used as a potential therapeutic agent for various diseases due to its antiviral, anti-inflammatory, and anticancer properties. Its pharmacological activities make it a candidate for the development of new drugs to treat viral infections, inflammatory conditions, and cancer.
Used in Antiviral Applications:
CHEMBRDG-BB 4012656 is used as an antiviral agent to inhibit the replication and spread of viruses, providing a potential treatment for viral infections.
Used in Anti-inflammatory Applications:
CHEMBRDG-BB 4012656 is used as an anti-inflammatory agent to reduce inflammation and alleviate symptoms associated with inflammatory conditions.
Used in Anticancer Applications:
CHEMBRDG-BB 4012656 is used as an anticancer agent to target and inhibit the growth of cancer cells, providing a potential treatment for various types of cancer.
Used in Antioxidant Applications:
CHEMBRDG-BB 4012656 is used as an antioxidant to neutralize free radicals and protect cells from oxidative damage, potentially reducing the risk of various diseases and promoting overall health.
Used in Drug Development:
CHEMBRDG-BB 4012656 is used as a natural source for drug development, providing a basis for the creation of new pharmaceutical compounds with potential therapeutic benefits. Further research is needed to optimize its properties and explore its full potential in the development of novel drugs.

Check Digit Verification of cas no

The CAS Registry Mumber 62995-79-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,9,9 and 5 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 62995-79:
(7*6)+(6*2)+(5*9)+(4*9)+(3*5)+(2*7)+(1*9)=173
173 % 10 = 3
So 62995-79-3 is a valid CAS Registry Number.
InChI:InChI=1/C10H22N2/c1-9(2)6-8(11-5)7-10(3,4)12-9/h8,11-12H,6-7H2,1-5H3

62995-79-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-N-methylamino-2,2,6,6-tetramethylpiperidine

1.2 Other means of identification

Product number -
Other names N,2,2,6,6-PENTAMETHYLPIPERIDIN-4-AMINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:62995-79-3 SDS

62995-79-3Relevant articles and documents

Scalable 9-Step Synthesis of the Splicing Modulator NVS-SM2

Abou-Hamdan, Hussein,Désaubry, Laurent

, p. 2954 - 2958 (2018/03/09)

NVS-SM2, the first activator of pre-mRNA splicing, displays remarkable pharmacological in vivo activities in models of spinal muscular atrophy. Herein we describe an improved approach to the synthesis of this compound, which features a convenient introduction of sterically encumbered amine moiety onto a fluoropyridazine intermediate.

Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening

Lalonde, Judith M.,Elban, Mark A.,Courter, Joel R.,Sugawara, Akihiro,Soeta, Takahiro,Madani, Navid,Princiotto, Amy M.,Kwon, Young Do,Kwong, Peter D.,Sch?n, Arne,Freire, Ernesto,Sodroski, Joseph,Smith III, Amos B.

supporting information; experimental part, p. 91 - 101 (2011/02/28)

The low-molecular-weight compound JRC-II-191 inhibits infection of HIV-1 by blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor and is therefore an important lead in the development of a potent viral entry inhibitor. Reported here is the use of two orthogonal screening methods, gold docking and ROCS shape-based similarity searching, to identify amine-building blocks that, when conjugated to the core scaffold, yield novel analogs that maintain similar affinity for gp120. Use of this computational approach to expand SAR produced analogs of equal inhibitory activity but with diverse capacity to enhance viral infection. The novel analogs provide additional lead scaffolds for the development of HIV-1 entry inhibitors that employ protein-ligand interactions in the vestibule of gp120 Phe 43 cavity.

In the Search for New Anticancer Drugs. 9. Synthesis and Anticancer Activity of Spin-Labeled Analogues of N,N:N',N':N'',N''-Tri-1,2-ethanediylphosphoric Triamide and N,N:N',N':N'',N''-Tri-1,2-ethanediylphosphorothioic Triamide

Sosnovsky, George,Paul, Buddha D.

, p. 782 - 788 (2007/10/02)

A number of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphoric triamide (TEPA) and N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (thio-TEPA) derivatives containing either two aziridine moieties (1a) or two (2-chloroethyl)amino functions (1b) and either a 2,2,6,6-tetramethylpiperidine, 1-oxy-2,2,6,6-tetramethylpiperidine or 1-hydroxy-2,2,6,6-tetramethylpiperidine component were synthesized and tested against lymphocytic leukemia P388 in mice.In a structure-activity comparison it was found that at optimum dose all compounds containing the nitroxyl radical were more active than the corresponding hydroxylamine derivatives.The open-chain compounds (1b) were less active than the corresponding aziridine ring compounds (1a).The replacement of the X = bridge in 1a with the X = N(CH3) group resulted in lowering of the anticancer activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 62995-79-3